AccessibilityHelpAbout Us
Ventripoint Diagnostics logo

Ventripoint Diagnostics(OTC) VPTDF

Market Cap$12.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-97%
5 Year-84%
1 Year-25%
1 Month-14%
$0.06
-1.08%
-0.00Today
Ventripoint Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.062026-09-17
Ventripoint Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.42%USD 0.072026-09-10
1 month-13.91%USD 0.072026-08-18
3 month-24.4%USD 0.082026-06-18
Year to date-38.52%USD 0.102025-12-31
1 year-24.5%USD 0.092025-09-17
3 year-57.73%USD 0.152023-09-18
5 year-84.26%USD 0.412021-09-17
Since inception-97%USD 2.152011-10-17

Ventripoint Diagnostics Financials at a Glance

Market Cap

$12.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$147.77K

Net Income (TTM)

-CA$2.32M

EPS (TTM)

-$0.01

P/E Ratio

-4.62

Dividend

$0.00

Beta (Volatility)

0.52 (Low)

Price

$0.06

Volume

12,630

Open

$0.06

Previous Close

$0.06

Daily Range

$0.06 - $0.06

52-Week Range

$0.06 - $0.14

Estimated Earnings Date

Nov 26, 2026

VPTDF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ventripoint Diagnostics

VentriPoint Diagnostics Ltd. is a medical technology company focused on developing diagnostic tools for assessing cardiac conditions. The company’s flagship product, the VentriPoint Medical System (VMS), utilizes advanced imaging technology to create accurate three-dimensional models of the heart, enhancing diagnostic capabilities for various heart diseases.

Products and Services
  • VentriPoint Medical System (VMS) for cardiac imaging
  • VMS+ software for 3D heart chamber modeling
  • Applications for congenital heart defects and cardiotoxicity
Growth Outlook
  • Expansion into new markets for cardiac diagnostics
  • Development of applications for COVID-19 related cardiac complications
  • Increased focus on research and development to enhance product offerings
Financial Highlights
  • Recent quarterly revenue of 19,583 CAD, consistent with previous quarters
  • Trailing twelve months (TTM) gross profit margin of 89.55%
  • Operating expenses of 527,584 CAD in the latest quarter, indicating ongoing investment in growth
VentriPoint Diagnostics Ltd. is positioned in the healthcare sector, specifically within medical devices, and is headquartered in Toronto, Canada. The company has been operational since 2004 and continues to innovate in the field of cardiac diagnostics. The VMS platform is designed to provide reliable volumetric and functional measurements, which are critical for effective patient management. As the demand for advanced cardiac care solutions grows, VentriPoint is strategically developing its product portfolio to address a wide range of heart-related conditions. The financial data indicates a commitment to research and development, which is essential for long-term growth and sustainability in the competitive medical technology landscape.
AI Generated • Sep 15, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Hugh MacNaught

Website

www.ventripoint.com

Headquarters

Toronto, ON M6P 1T4, CA

VPTDF Financials

Key Financial Metrics (TTM)

Gross Margin

89.55%

Operating Margin

-1624.48%

Net Income Margin

-1568.50%

Return on Equity

56.40%

Return on Capital

N/A

Return on Assets

-378.80%

Earnings Yield

-21.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

192.88M

Volume

12.63K

Avg. Volume

128.30K

Financials (TTM)

Gross Profit

CA$132.35K

Operating Income

-CA$2.40M

EBITDA

-CA$1.34M

Operating Cash Flow

-CA$1.90M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$1.90M

Cash & ST Invst.

CA$333.63K

Total Debt

CA$2.62M

Ventripoint Diagnostics Performance Analysis

Ventripoint Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 52,361N/A
20232023-12-31CAD 36,440-30.4%
20242024-12-31CAD 69,47190.6%
20252025-12-31CAD 128,76985.4%
Ventripoint Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31-95.9%
Q12026-03-31355.4%
Q22026-06-30N/A
Ventripoint Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.025.7%
20232023-12-31CAD -0.02-4.2%
20242024-12-31CAD -0.02-1.3%
20252025-12-31CAD -0.01-39.2%
Ventripoint Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3043.0%
Q42025-12-3177.8%
Q12026-03-31-270.0%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$19.58K

N/A

Gross Profit

CA$19.58K

+274.6%

Gross Margin

100.00%

N/A

Market Cap

$12.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.13M

N/A

Employees

3

N/A

Net Income

-CA$683.00K

+47.0%

EBITDA

CA$0.00

+100.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$333.63K

+34.1%

Total Debt

CA$2.62M

+18.0%

Accounts Receivable

CA$0.00

-100.0%

Inventory

CA$94.24K

N/A

Long Term Debt

CA$59.63K

-64.0%

Short Term Debt

CA$2.56M

+24.6%

Return on Assets

-3.79%

N/A

Return on Invested Capital

63.62%

N/A

Free Cash Flow

-CA$614.42K

-12.3%

Operating Cash Flow

-CA$614.42K

-12.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALRTFALR Technologies Inc.
$0.02+0.00%
ASAPFAurora Spine Corporation
$0.10+0.00%
NUMIFNuminus Wellness Inc.
$0.02+14.29%
LUFFFHerbal Dispatch Inc.
$0.02+13.30%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$44.99-10.22%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$114.82+10.44%
INTCIntel
$108.80+7.67%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.53-5.12%

Questions About VPTDF

What is the current price of Ventripoint Diagnostics?

Ventripoint Diagnostics is trading at $0.06 per share.

What is the 52-week range for Ventripoint Diagnostics?

Over the past 52 weeks, Ventripoint Diagnostics has traded between $0.06 and $0.14.

How much debt does Ventripoint Diagnostics have?

As of the most recent reporting period, Ventripoint Diagnostics reported total debt of CA$1.90M.

How much cash does Ventripoint Diagnostics have on hand?

Ventripoint Diagnostics reported CA$40.41K in cash and cash equivalents in its most recent financial results.

What is Ventripoint Diagnostics’s dividend yield?

Ventripoint Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services